Moderna's (MRNA) phase 3 adjuvant melanoma data establishes clinical proof of concept for individualized neoantigen therapies, or INT, while interim data from a phase 2 kidney cancer trial would provide the next input into the potential breadth of opportunity for the drug, Morgan Stanley said in a note Tuesday.
The investment firm raised its peak sales estimate for individualized neoantigen therapies to $32 billion from $24 billion, profit-share assumption, and terminal growth rate in the firm's discounted cash flow model following the presentation of the phase 3 melanoma data
Morgan Stanley said a key opinion leader called the phase 3 melanoma results groundbreaking, citing a 0.58 hazard ratio for recurrence-free survival, and projected a 60% to 70% probability of success for INT in renal cell carcinoma versus about 50% in lung cancer.
The next key catalyst is an interim analysis of Moderna's phase 2 renal cell carcinoma trial, expected later this year or early 2027, the firm said.
Morgan Stanley maintained its equal weight rating on the stock and raised its price target to $200 from $95.
Moderna shares were down 3.9% in Tuesday trading.
Price: 206.91, Change: -8.37, Percent Change: -3.89
Comments